PriceTargets.com logo

NASDAQ:PLSE - Pulse Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.00
  • Forecasted Upside: 146.56 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$17.44 As of 06/16/2021 01:00 AM ET
▲ +0.19 (1.10%)
1 month | 3 months | 12 months
Get New Pulse Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLSE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLSE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$43.00
▲ +146.56% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Pulse Biosciences in the last 3 months. The average price target is $43.00, with a high forecast of $46.00 and a low forecast of $40.00. The average price target represents a 146.56% upside from the last price of $17.44.

Buy

The current consensus among 2 contributing investment analysts is to buy stock in Pulse Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/11/2021Maxim GroupInitiated CoverageBuy$40.00High
i
2/4/2021HC WainwrightBoost Price TargetBuy$40.00 ➝ $46.00High
i
1/26/2021HC WainwrightBoost Price TargetBuy$16.00 ➝ $40.00Medium
i
5/12/2020HC WainwrightUpgradeNeutral ➝ Buy$6.00 ➝ $16.00High
i
Rating by S. Ramakanth at HC Wainwright
3/17/2020HC WainwrightReiterated RatingHold$6.00High
i
Rating by S. Ramakanth at HC Wainwright
2/14/2020HC WainwrightDowngradeBuy ➝ Neutral$26.00 ➝ $6.00High
i
Rating by S. Ramakanth at HC Wainwright
5/1/2019HC WainwrightReiterated RatingBuyLow
i
Rating by S. Ramakanth at HC Wainwright
2/25/2019HC WainwrightInitiated CoverageBuy ➝ Buy$27.00High
i
(Data available from 6/16/2016 forward)
Pulse Biosciences logo
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Read More

Today's Range

Now: $17.44
$16.81
$17.65

50 Day Range

MA: $19.00
$16.31
$22.02

52 Week Range

Now: $17.44
$8.76
$45.82

Volume

51,911 shs

Average Volume

113,431 shs

Market Capitalization

$461.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Pulse Biosciences?

The following equities research analysts have issued reports on Pulse Biosciences in the last year: HC Wainwright, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for PLSE.

What is the current price target for Pulse Biosciences?

2 Wall Street analysts have set twelve-month price targets for Pulse Biosciences in the last year. Their average twelve-month price target is $43.00, suggesting a possible upside of 146.6%. HC Wainwright has the highest price target set, predicting PLSE will reach $46.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $40.00 for Pulse Biosciences in the next year.
View the latest price targets for PLSE.

What is the current consensus analyst rating for Pulse Biosciences?

Pulse Biosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLSE will outperform the market and that investors should add to their positions of Pulse Biosciences.
View the latest ratings for PLSE.

What other companies compete with Pulse Biosciences?

Other companies that are similar to Pulse Biosciences include Inovio Pharmaceuticals, Luminex, Silk Road Medical, Cardiovascular Systems, Pulmonx, Alphatec, Treace Medical Concepts, MiMedx Group, OrthoPediatrics, LeMaitre Vascular, CryoLife, Atrion, SI-BONE, Tactile Systems Technology and Bioventus.

How do I contact Pulse Biosciences' investor relations team?

Pulse Biosciences' physical mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company's listed phone number is 510-906-4600 and its investor relations email address is [email protected] The official website for Pulse Biosciences is www.pulsebiosciences.com.